Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Subjects With Relapsed/Refractory Multiple Myeloma

NCT06668792 is registered in ClinicalTrials.gov with Biocad as lead sponsor.

NCT NCT06668792
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06668792 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Subjects With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Biocad
Phase
Phase 2
Overall status
Recruiting
Start date
December 26, 2024
Completion date
July 31, 2028
Enrollment
100 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory multiple myeloma